---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-26-000049"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2026-05-14T10:16:31+00:00"
generated_at: "2026-05-14T10:20:45.668865+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Editas reports EDIT-401 achieves ≥90% LDL-C reduction in NHPs; durable through 6 months

## Summary
- Single dose of EDIT-401 achieved ≥90% mean LDL-C reduction across all dose groups in non-human primates.
- Reduction durable through ~6 months; achieved with 10-40% functional editing of LDLR alleles and ≥6-fold hepatic LDLR protein increase.
- Promising preclinical safety profile: no adverse clinical observations at 1.5 mg/kg; undetectable oocyte delivery.
- Data in Ldlr loss-of-function mice suggest dose adjustments may not be needed for HeFH patients.
- Data support broader upregulation platform and continued advancement toward first-in-human clinical development.

## SEC filing metadata
- accession: 0001650664-26-000049
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2026-05-14T10:16:31+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066426000049/0001650664-26-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066426000049/edit-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-26-000049
- JSON: https://secwatch.observer/filing/0001650664-26-000049.json
- Plain text: https://secwatch.observer/filing/0001650664-26-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.